Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is simply a statement bargain from each eleven analysts covering the stock. While the people terms ranges from $12 to $30, the median terms people of $19 translates to an upside imaginable of 79.92%.

On December 18, Raymond James initiated sum connected Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with a ‘Strong Buy’ standing and a terms people of $25, citing coagulated results from 2 Phase 1/2 objective trials and encouraging feedback from the FDA. With that said, the company’s pb candidate, LX2006, an AAV cistron therapy for cardiomyopathy associated with Friedreich’s Ataxia, is “well-positioned for success” successful its pivotal trial, the expert asserted.

Photo by National Cancer Institute connected Unsplash

Raymond James expects the banal to summation momentum successful 2026 pursuing a finalized pivotal protocol with the FDA and archetypal impervious of conception information connected LX2020, an unmodeled cistron therapy asset. The steadfast anticipates LX2006 gross of $14.1 cardinal successful FY27, going arsenic precocious arsenic $805.3 cardinal successful FY32.

Earlier connected December 10, Cantor Fitzgerald reaffirmed an ‘Overweight’ standing connected Lexeo Therapeutics, Inc. (NASDAQ:LXEO), with a terms people of $19. The reaffirmation, implying an upside imaginable of astir 80%, is driven by the prospects of the company’s PKP2-ACM program. The expert highlighted that the marketplace remains focused connected Lexeo’s Friedreich’s ataxia programme and the PKP2-ACM programme appears “under the radar,” peculiarly arsenic the upcoming information expected successful the adjacent period could displacement marketplace perception.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is simply a New York-based clinical-stage familial medicine company. Founded successful 2017, the institution has a pipeline of programs, including LX2006, LX2020, and LX2021.

While we admit the imaginable of LXEO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.